Seonhee Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Seonhee Kim has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Cuk-Seong Kim
Department of Physiology & Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea
3 shared publications - Byeong Hwa Jeon
Department of Physiology, College of Medicine, Chungnam National University, Daejeon 35015, Korea
2 shared publications - Dong Woon Kim
Department of Oral Anatomy and Neurobiology, Kyung Hee University College of Dentistry, Seoul, Republic of Korea
2 shared publications - Harsha Nagar
Department of Physiology & Medical Science, School of Medicine, Chungnam National University, Daejeon, 301-747, Republic of Korea
2 shared publications Ikjun Lee
Department of Physiology & Medical Science, School of Medicine, Chungnam National University, Daejeon, 301-747, Republic of Korea
2 shared publications- Kaikobad Irani
Division of Cardiovascular Medicine, University of Iowa Carver College of Medicine, Iowa City, USA
2 shared publications
Latest Publications
- Open Access
- 1 December 2023
- Published by Korean Society of Clinical Oncology in Korean Journal of Clinical Oncology
- Vol. 19 (2) , 60-68
The relative isoform expression levels of isocitrate dehydrogenase in breast cancer: IDH2 is a potential target in MDA-MB-231 cells
Purpose: The isocitrate dehydrogenase (IDH) family plays an essential role in metabolism and energy production. The relative expression levels of IDH isoforms (IDH1, IDH2, and IDH3) have prognostic significance in several malignancies, including breast carcinoma. However, the IDH isozyme expression levels in different cancer stages and types have not been determined in breast carcinoma tissues.Methods: We analyzed the messenger RNA (mRNA) and protein levels of IDH (IDH1, IDH2, and IDH3A) and α-ketoglutarate (α-KG) in 59 breast carcinoma tissues.Results: The mRNA level of IDH2 was significantly increased at stages 2 and 3 in triple-negative and (ER-/PR-/HER+) breast cancers. However, the elevated α-KG level was only observed in stages 2 and 3, with no differences in the various breast carcinoma types. Western blotting analysis showed that IDH2 protein expression increased in the patient tissues and cell lines. An in vitro study showed IDH2 downregulation in the triple-negative breast cancer cell line MDA-MB-231 that inhibited cell proliferation and migration and induced cell cycle arrest in the G0/G1 phase.Conclusion: These findings suggest that different from IDH1 and IDH3, IDH2 is more highly expressed in stages 2 and 3 breast cancer tissues, especially in triple-negative breast cancer. IDH2 potentially serves as a target to detect unknown mechanisms in breast cancer.
- 1 December 2023
- Published by Korean Society of Clinical Oncology in Korean Journal of Clinical Oncology
- Vol. 19 (2) , 60-68
Open AccessThe relative isoform expression levels of isocitrate dehydrogenase in breast cancer: IDH2 is a potential target in MDA-MB-231 cells
Purpose: The isocitrate dehydrogenase (IDH) family plays an essential role in metabolism and energy production. The relative expression levels of IDH isoforms (IDH1, IDH2, and IDH3) have prognostic significance in several malignancies, including breast carcinoma. However, the IDH isozyme expression levels in different cancer stages and types have not been determined in breast carcinoma tissues.Methods: We analyzed the messenger RNA (mRNA) and protein levels of IDH (IDH1, IDH2, and IDH3A) and α-ketoglutarate (α-KG) in 59 breast carcinoma tissues.Results: The mRNA level of IDH2 was significantly increased at stages 2 and 3 in triple-negative and (ER-/PR-/HER+) breast cancers. However, the elevated α-KG level was only observed in stages 2 and 3, with no differences in the various breast carcinoma types. Western blotting analysis showed that IDH2 protein expression increased in the patient tissues and cell lines. An in vitro study showed IDH2 downregulation in the triple-negative breast cancer cell line MDA-MB-231 that inhibited cell proliferation and migration and induced cell cycle arrest in the G0/G1 phase.Conclusion: These findings suggest that different from IDH1 and IDH3, IDH2 is more highly expressed in stages 2 and 3 breast cancer tissues, especially in triple-negative breast cancer. IDH2 potentially serves as a target to detect unknown mechanisms in breast cancer.
- 1 September 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 503 (3) , 1805-1811
Isocitrate dehydrogenase 2 deficiency induces endothelial inflammation via p66sh-mediated mitochondrial oxidative stress
- 1 September 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 503 (3) , 1805-1811
Isocitrate dehydrogenase 2 deficiency induces endothelial inflammation via p66sh-mediated mitochondrial oxidative stress
- Open Access
- 23 February 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (2) , e0192693
CR6 interacting factor 1 deficiency promotes endothelial inflammation by SIRT1 downregulation
CR6 interacting factor 1 (CRIF1) deficiency impairs mitochondrial oxidative phosphorylation complexes, contributing to increased mitochondrial and cellular reactive oxygen species (ROS) production. CRIF1 downregulation has also been revealed to decrease sirtuin 1 (SIRT1) expression and impair vascular function. Inhibition of SIRT1 disturbs oxidative energy metabolism and stimulates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)-induced inflammation. Therefore, we hypothesized that both CRIF1 deficiency-induced mitochondrial ROS production and SIRT1 reduction play stimulatory roles in vascular inflammation. Plasma levels and mRNA expression of proinflammatory cytokines (tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6) were markedly elevated in endothelium-specific CRIF1-knockout mice and CRIF1-silenced endothelial cells, respectively. Moreover, CRIF1 deficiency-induced vascular adhesion molecule-1 (VCAM-1) expression was consistently attenuated by the antioxidant N-acetyl-cysteine and NF-κB inhibitor (BAY11). We next showed that siRNA-mediated CRIF1 downregulation markedly activated NF-κB. SIRT1 overexpression not only rescued CRIF1 deficiency-induced NF-κB activation but also decreased inflammatory cytokines (TNF-α, IL-1β, and IL-6) and VCAM-1 expression levels in endothelial cells. These results strongly suggest that CRIF1 deficiency promotes endothelial cell inflammation by increasing VCAM-1 expression, elevating inflammatory cytokines levels, and activating the transcription factor NF-κB, all of which were inhibited by SIRT1 overexpression.
- 23 February 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (2) , e0192693
Open AccessCR6 interacting factor 1 deficiency promotes endothelial inflammation by SIRT1 downregulation
CR6 interacting factor 1 (CRIF1) deficiency impairs mitochondrial oxidative phosphorylation complexes, contributing to increased mitochondrial and cellular reactive oxygen species (ROS) production. CRIF1 downregulation has also been revealed to decrease sirtuin 1 (SIRT1) expression and impair vascular function. Inhibition of SIRT1 disturbs oxidative energy metabolism and stimulates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)-induced inflammation. Therefore, we hypothesized that both CRIF1 deficiency-induced mitochondrial ROS production and SIRT1 reduction play stimulatory roles in vascular inflammation. Plasma levels and mRNA expression of proinflammatory cytokines (tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6) were markedly elevated in endothelium-specific CRIF1-knockout mice and CRIF1-silenced endothelial cells, respectively. Moreover, CRIF1 deficiency-induced vascular adhesion molecule-1 (VCAM-1) expression was consistently attenuated by the antioxidant N-acetyl-cysteine and NF-κB inhibitor (BAY11). We next showed that siRNA-mediated CRIF1 downregulation markedly activated NF-κB. SIRT1 overexpression not only rescued CRIF1 deficiency-induced NF-κB activation but also decreased inflammatory cytokines (TNF-α, IL-1β, and IL-6) and VCAM-1 expression levels in endothelial cells. These results strongly suggest that CRIF1 deficiency promotes endothelial cell inflammation by increasing VCAM-1 expression, elevating inflammatory cytokines levels, and activating the transcription factor NF-κB, all of which were inhibited by SIRT1 overexpression.
- Open Access
- 1 March 2008
- Published by Wiley in The FASEB Journal
- Vol. 22 (S1) , 1110.2-1110
Effects of polysaccharides from Salicornia herbacea on proliferation and apoptotic activity in mouse splenocytes
This study investigated the proliferation and apoptotic activities of Salicornia herbacea in mouse splenocytes. Crude (CSP) and other kinds of fine polysaccharides (SPI and SPII) were prepared from Salicornia herbacea by ultrafiltration and gel filtration chromatography. Mouse splenocytes were treated with CSP, SPI or SPII (1, 2, 4, 8 mg/ml). The proliferation and apoptosis of the cells were used as indices for immunomodulating activity. The effect of proliferation was evaluated using MTS assay. Apoptosis of the cells was assayed quantitatively by Annexin V technique using a flow cytometry. In results, the proliferation was more increased in the SPI and SPII treated cells compared to the CSP treated cells. The most proliferation was shown in the splenocytes cultured with SPI at the concentration of 8 mg/ml for 24hr. The proliferation of splenocytes and separated T‐cells was higher (5.5 times and 3.7 times, repectively) than the control. Treatment of the mouse splenocytes with the SPI and SPII suppressed apoptosis of the cells. Moreover, those proliferation and suppression of the apoptotic death were in dose‐dependent manner. In conclusion, polysaccharides from Salicornia herbacea may have a beneficial effect on immunomodulating activity. (This work was supported by BK21, NURI, and BPRC)
- 1 March 2008
- Published by Wiley in The FASEB Journal
- Vol. 22 (S1) , 1110.2-1110
Open AccessEffects of polysaccharides from Salicornia herbacea on proliferation and apoptotic activity in mouse splenocytes
This study investigated the proliferation and apoptotic activities of Salicornia herbacea in mouse splenocytes. Crude (CSP) and other kinds of fine polysaccharides (SPI and SPII) were prepared from Salicornia herbacea by ultrafiltration and gel filtration chromatography. Mouse splenocytes were treated with CSP, SPI or SPII (1, 2, 4, 8 mg/ml). The proliferation and apoptosis of the cells were used as indices for immunomodulating activity. The effect of proliferation was evaluated using MTS assay. Apoptosis of the cells was assayed quantitatively by Annexin V technique using a flow cytometry. In results, the proliferation was more increased in the SPI and SPII treated cells compared to the CSP treated cells. The most proliferation was shown in the splenocytes cultured with SPI at the concentration of 8 mg/ml for 24hr. The proliferation of splenocytes and separated T‐cells was higher (5.5 times and 3.7 times, repectively) than the control. Treatment of the mouse splenocytes with the SPI and SPII suppressed apoptosis of the cells. Moreover, those proliferation and suppression of the apoptotic death were in dose‐dependent manner. In conclusion, polysaccharides from Salicornia herbacea may have a beneficial effect on immunomodulating activity. (This work was supported by BK21, NURI, and BPRC)